HOME
  Home > How to Use DEFINITY® > Intellipin®  

How to use DEFINITY®: Using the INTELLIPIN® (Dispensing Pin)


INTELLIPIN Dispensing Pin

INTELLIPIN® Dispensing Pin

For activated DEFINITY® (Perflutren Liquid
Microsphere) Injectable Suspension only.

 

A Simple And Efficient Alternative To Needles

Instructions For Use. For single use only. Do not resterilize.

Intellipin 1
Following activation with VIALMIX®, remove DEFINITY® vial cap and insert INTELLIPIN® into vial.
Intellipin 2
Remove blue cap from female port of INTELLIPIN®, attach syringe to female port.
Intellipin 3
Invert DEFINITY® vial and withdraw using syringe.

Destroy after single use.


INTELLIPIN® Ordering Information

INDICATIONS

Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

The safety and efficacy of DEFINITY® with exercise stress or pharmacologic stress testing have not been established.

CONTRAINDICATIONS

Do not administer DEFINITY® to patients with known or suspected right-to-left, bi-directional or transient right-to-left cardiac shunts, by intra-arterial injection, or to patients with known hypersensitivity to perflutren.

IMPORTANT SAFETY INFORMATION

WARNING: Serious Cardiopulmonary Reactions 

Serious cardiopulmonary reactions, including fatalities, have occurred during or following perflutren-containing microsphere administration.

  • Assess all patients for the presence of any condition that precludes DEFINITY® administration (see CONTRAINDICATIONS).
  • In patients with pulmonary hypertension or unstable cardiopulmonary conditions, monitor vital sign measurements, electrocardiography and cutaneous oxygen saturation during and for at least 30 minutes after DEFINITY® administration (see WARNINGS).
  • Always have resuscitation equipment and trained personnel readily available.


In post marketing use, rare but serious cardiopulmonary or anaphylactoid reactions have been reported during or shortly following perflutren-containing microsphere administration (see ADVERSE REACTIONS). The risk for these reactions may be increased among patients with pulmonary hypertension or unstable cardiopulmonary conditions. It is not always possible to reliably establish a causal relationship to drug exposure due to the presence of underlying cardiopulmonary disease.

Please See Full Prescribing Information and Letter to Healthcare Providers.